Infectious Disease / Microbiology Updates
6.64K subscribers
31 photos
3 videos
23 files
3.72K links
All the atest articles, research and news from worlds leading Infectious Disease Journals.

Discussion group
https://t.me/Professional_Medical_Discussion
Download Telegram
[Newsdesk] Research in brief
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00129-5/fulltext?rss=yes

A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.
3👍1
[Comment] Structural stigma: an urgent intervention priority in Africa
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00359-5/fulltext?rss=yes

Improved access to antiretroviral therapy (ART) for people with HIV has greatly affected the trajectory of the global HIV pandemic, enabling people with HIV to lead long, healthy lives and curtailing the number of people who newly acquire HIV. Between 2000 and 2024, the number of people with HIV accessing ART globally increased from 370 000 to 31·6 million.1 Over the same period, the percentage of people with HIV accessing ART increased from 0% to 83% in Africa,2 a region that accounts for nearly two-thirds of the 40·8 million people with HIV worldwide.